$CUBT

Curative Biotechnology announced a 1-for-150 reverse stock split of its common stock, effective March 23, 2026, aimed at strengthening its capital structure and preparing for an OTCQB uplisting. This move reduces outstanding shares from 1.02 billion to 6.8 million and is part of a broader strategy to advance its metformin-based ophthalmology platform through planned human and K9 clinical studies. The company is actively pursuing manufacturing agreements and evaluating strategic relationships to support its clinical development objectives.